Melflufen Plus Dexamethasone Improved Survival Over Pomalidomide Combo for Relapsed/Refractory Myeloma
January 25, 2022

Improved progression-free survival was observed when treating patients with relapsed/refractory multiple myeloma with melphalan flufenamide plus dexamethasone compared with pomalidomide plus dexamethasone.

Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL
January 25, 2022

Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.

Sugemalimab/Chemotherapy Combo Yields Statistically Significant Improvement in Overall Survival vs Placebo for NSCLC
January 25, 2022

Patients with stage IV non–small cell lung cancer treated with sugemalimab plus chemotherapy experienced a prolonged overall survival benefit compared with those who received placebo and chemotherapy.

Consolidation Therapy Post-Transplant in Multiple Myeloma
January 25, 2022

The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.

Transplant-Eligible Multiple Myeloma: When to Move to Transplant
January 25, 2022

Recommendations regarding the appropriate number of cycles of induction therapy before sending a patient with multiple myeloma for stem cell transplantation.

Lenvatinib Yields Survival Benefit, Manageable Toxicities in Recurrent HCC After Liver Transplantation
January 24, 2022

Patients with recurrent hepatocellular carcinoma after liver transplantation were treated with lenvatinib and saw promising efficacy.

Darovasertib/Crizotinib Combo Achieves Promising Responses in Pretreated Metastatic Uveal Melanoma
January 24, 2022

Patients with heavily pretreated metastatic uveal melanoma appeared to benefit from treatment with a synthetic lethal combination of darovasertib and crizotinib.

Depressive Symptoms and Mental HRQOL Prior to Diagnosis Did Not Affect Survival in Older Population With Multiple Myeloma
January 24, 2022

A retrospective study did not find any associations between survival of older patients with multiple myeloma and pre-diagnosis depressive symptoms and mental health-related quality of life.

FDA Lifts Partial Clinical Hold on Early-Phase Study of KO-539 in AML
January 24, 2022

The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.

Fixed Duration Venetoclax/Rituximab Combo May Prolong Disease Control in Chronic Lymphocytic Leukemia
January 24, 2022

Patients with chronic lymphocytic leukemia treated with fixed duration venetoclax/rituximab may experience prolonged disease control vs bendamustine/rituximab.